Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 35%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

DexCom is compelling because it combines a defensible CGM leadership position with expanding demand beyond intensive insulin users, supported by the CONNECT trial’s 6-month randomized data showing a −1.6% A1c reduction vs. −0.7% control, ~21% TIR improvement, and ~97% adherence in T2NIT patients. The consumer pivot is also strengthening the growth case: Stelo/NutriSense and the redesigned app show that meal logging, daily insights, coaching, and notifications can drive engagement more effectively than sensor readings alone, improving retention and utilization in broader OTC and non-intensive diabetes markets. Financially, DexCom’s 2026 revenue guidance of $5.16B-$5.25B, 63-64% adjusted gross margin, 22.2% adjusted operating margin, and $2.42B of cash support a scalable, profitable model with meaningful upside from CMS T2NIT coverage and 15-day rollout adoption.

Bears say

DexCom is facing a challenging fundamental setup because its growth depends on CGM penetration continuing to expand, yet competitive products could erode its moat and make sustained share gains harder to achieve. Regulatory hurdles may delay new product launches, while payor and CMS pricing pressure, combined with the high investment required to compete, could keep profitability difficult despite stable hardware performance and reliable alert functionality. The stock also appears vulnerable because it trades at a significant premium multiple, so any slowdown in adoption or weaker-than-expected product innovation could amplify downside risk.

DexCom (DXCM) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 35% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 20 analysts, DexCom (DXCM) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.